PCM
ZVRA icon

Prelude Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

Prelude Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$339K Sell
23,640
-2,301
-9% -$25.6K 0.02% 705
2026
Q1 		$242K Buy
25,941
+14,441
+126% +$130K 0.02% 814
2025
Q4 		$103K Sell
11,500
-4,100
-26% -$38.8K 0.01% 1179
2025
Q3 		$148K Buy
+15,600
New +$156K 0.01% 1001

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Prelude Capital Management's ZVRA Position: Q2 2026 in Review

Prelude Capital Management reduced its Zevra Therapeutics (ZVRA) stake by 8.9% in Q2 2026, selling an estimated $25.6K and leaving 23,640 shares worth $339K. The position accounts for 0.02% of the portfolio, ranked #705.

Prelude Capital Management first reported a position in ZVRA in Q3 2025 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

  • Prelude Capital Management held 23,640 shares of Zevra Therapeutics worth $339K as of Q2 2026.
  • Prelude Capital Management sold 2,301 Zevra Therapeutics shares in Q2 2026, an estimated $25.6K.
  • Zevra Therapeutics made up 0.02% of Prelude Capital Management's portfolio in Q2 2026, its #705 holding.
  • Prelude Capital Management first reported a position in Zevra Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.